Pancreatic Cancer Research

ResearcherChiba Cancer CenterActive in the last 2 years

Hideshi Ishii

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0632-6517; OpenAlex author ID A5069574401. Sources: OpenAlex.

Their work

Papers
24 (first author 0, last author 19)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: 4 papers · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 6 papers · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper

Papers 24

  1. Recent Findings in N6-Methyladenosine Modification and Significance in Pancreatic Cancer. Last author DOI 10.1002/cam4.70934↗
  2. High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. Last author DOI 10.1111/cas.16152↗
  3. Significance of signal recognition particle 9 nuclear translocation: Implications for pancreatic cancer prognosis and functionality. Last author DOI 10.3892/ijo.2024.5662↗
  4. Revealing neuropilin expression patterns in pancreatic cancer: From single‑cell to therapeutic opportunities (Review). Last author DOI 10.3892/ol.2024.14247↗
  5. Multifaced roles of desmoplastic reaction and fibrosis in pancreatic cancer progression: Current understanding and future directions. Last author DOI 10.1111/cas.15890↗
  6. Role of RNA methylation in the regulation of pancreatic cancer stem cells (Review). Last author DOI 10.3892/ol.2023.13922↗
  7. Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cnr2.1582↗
  8. Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. Last author DOI 10.1016/j.isci.2022.104659↗
  9. N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-15196-5↗
  10. Circulating cancer-associated extracellular vesicles as early detection and recurrence biomarkers for pancreatic cancer. Co-author DOI 10.1111/cas.15500↗
  11. Emerging roles of long noncoding and circular RNAs in pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fphys.2022.1025923↗
  12. Pancreatic Cancer Research beyond DNA Mutations. Last author DOI 10.3390/biom12101503↗
  13. Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer. Last author DOI 10.18632/oncotarget.28035↗
  14. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  15. Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. Last author DOI 10.3390/cells9071645↗
  16. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Co-author DOI 10.3892/ijo.2017.4219↗
  17. Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. Last author DOI 10.3892/ol.2018.8357↗
  18. c-Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer. Last author DOI 10.3892/ol.2018.8793↗
  19. The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer. Last author DOI 10.3892/ol.2018.8795↗
  20. A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients. Last author DOI 10.3892/ijo.2015.3258↗
  21. Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. Co-author DOI 10.3892/ol.2015.4057↗
  22. The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer. Last author DOI 10.3892/mco.2015.490↗
  23. Cyclin G2: A novel independent prognostic marker in pancreatic cancer. Last author DOI 10.3892/ol.2015.3667↗
  24. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Last author DOI 10.1038/bjc.2014.454↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 19 shared papers, 2014–2024 · strength 1.87
  2. Hidetoshi Eguchi · 18 shared papers, 2014–2024 · strength 1.79
  3. Tomoaki Hara · 8 shared papers, 2022–2025 · strength 1.43
  4. Hiromichi Sato · 7 shared papers, 2022–2024 · strength 1.17
  5. Sikun Meng · 6 shared papers, 2023–2025 · strength 1.16
  6. Yoshiko Tsuji · 6 shared papers, 2022–2024 · strength 1.03
  7. Kazuki Sasaki · 6 shared papers, 2022–2024 · strength 0.88
  8. Kazuhiko Ogawa · 6 shared papers, 2018–2024 · strength 0.83
  9. Shotaro Tatekawa · 5 shared papers, 2022–2024 · strength 0.76
  10. Daisaku Yamada · 6 shared papers, 2018–2024 · strength 0.65
  11. Ayumu Asai · 5 shared papers, 2018–2022 · strength 0.51
  12. Yoshito Tomimaru · 7 shared papers, 2014–2024 · strength 0.48
  13. Hirofumi Akita · 4 shared papers, 2018–2022 · strength 0.43
  14. Ryota Chijimatsu · 3 shared papers, 2021–2022 · strength 0.39
  15. Tadafumi Asaoka · 5 shared papers, 2016–2022 · strength 0.36
  16. Yu Takeda · 3 shared papers, 2020–2024 · strength 0.36
  17. Yoshifumi Iwagami · 3 shared papers, 2018–2024 · strength 0.36
  18. Hiroaki Nagano · 6 shared papers, 2014–2018 · strength 0.28
  19. Hidenori Takahashi · 2 shared papers, 2022–2024 · strength 0.27
  20. Kunihito Gotoh · 3 shared papers, 2018–2022 · strength 0.26
  21. Shigeru Marubashi · 5 shared papers, 2015–2018 · strength 0.24
  22. Katsunori Matsushita · 2 shared papers, 2018–2022 · strength 0.20
  23. Shinichiro Hasegawa · 4 shared papers, 2014–2016 · strength 0.17
  24. Yusuke Yoshioka · 1 shared paper, 2022 · strength 0.15
  25. Takahiro Ochiya · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.